Friday, July 10, 2026
🇺🇸 FDA

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen Cilag International NV

Janssen Cilag International clinical programs — 46 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Janssen Cilag International projects

46 ClinicalTrials.gov programs sponsored by Janssen Cilag International.

Janssen Cilag International has 46 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

46 programs

Clinical programs

  1. Amivantamab

    Janssen Cilag International NV

    Colorectal Neoplasms

    phase 3 mab active

    1 trial

  2. Apalutamide

    Janssen Cilag International NV

    Metastatic Castrate-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. Canagliflozin

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  4. Cilta-cel

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  6. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  7. Esketamine

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  8. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  9. Golimumab 1 mg per kg

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule terminated

    1 trial

  10. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  11. Ibrutinib

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  12. Icotrokinra

    Janssen Cilag International NV

    Crohn Disease

    phase 3 small molecule active

    1 trial

  13. JNJ-77242113

    Janssen Cilag International NV

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. LHRHa

    Janssen Cilag International NV

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial

  15. Nipocalimab

    Janssen Cilag International NV

    Sjogrens Syndrome

    phase 3 small molecule active

    1 trial

  16. Olanzapine

    Janssen Cilag International NV

    Bipolar Disorder

    phase 3 small molecule completed

    1 trial

  17. Paliperidone palmitate

    Janssen Cilag International NV

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  18. Pimodivir 600 mg

    Janssen Cilag International NV

    Influenza A

    phase 3 small molecule terminated

    1 trial

  19. Rituximab

    Janssen Cilag International NV

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  20. Tapentadol IR 50 mg

    Janssen Cilag International NV

    Hallux Valgus

    phase 3 small molecule completed

    1 trial

  21. Ustekinumab Dose Based on BSA and Body Weight

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  22. AL-335

    Janssen Cilag International NV

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  23. Apalutamide

    Janssen Cilag International NV

    Salivary Gland Neoplasms

    phase 2 small molecule active

    1 trial

  24. Azacitidine

    Janssen Cilag International NV

    Myelodysplastic Syndromes

    phase 2 small molecule terminated

    1 trial

  25. Cetrelimab

    Janssen Cilag International NV

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  26. Erdafitinib Intravesical Delivery System

    Janssen Cilag International NV

    Non-Muscle Invasive Bladder Neoplasms

    phase 2 small molecule active

    1 trial

  27. Guselkumab

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 mab active

    1 trial

  28. JNJ-40411813

    Janssen Cilag International NV

    Focal Onset Seizures

    phase 2 small molecule completed

    1 trial

  29. JNJ-64281802

    Janssen Cilag International NV

    Dengue

    phase 2 small molecule terminated

    2 trials

  30. JNJ-73763989

    Janssen Cilag International NV

    Hepatitis B, Chronic

    phase 2 small molecule terminated

    1 trial

  31. JNJ-77242113

    Janssen Cilag International NV

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  32. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Viruses

    phase 2 small molecule terminated

    1 trial

  33. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  34. Placebo

    Janssen Cilag International NV

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  35. Rilematovir

    Janssen Cilag International NV

    Respiratory Syncytial Virus

    phase 2 small molecule terminated

    1 trial

  36. Rilpivirine

    Janssen Cilag International NV

    HIV-1

    phase 2 small molecule completed

    1 trial

  37. Siltuximab

    Janssen Cilag International NV

    Multicentric Castleman's Disease

    phase 2 small molecule completed

    1 trial

  38. TMC207

    Janssen Cilag International NV

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  39. Acetaminophen

    Janssen Cilag International NV

    Healthy

    phase 1 small molecule completed

    1 trial

  40. Ad26.COV2.S

    Janssen Cilag International NV

    Healthy

    phase 1 mab completed

    1 trial

  41. Hydromorphone 16 mg

    Janssen Cilag International NV

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  42. JNJ-53718678

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 1 small molecule terminated

    1 trial

  43. JNJ-56021927

    Janssen Cilag International NV

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule completed

    1 trial

  44. Guselkumab

    Janssen Cilag International NV

    Arthritis, Psoriatic

    approved small molecule active

    3 trials

  45. OROS hydromorphone

    Janssen Cilag International NV

    Cancer Pain

    approved small molecule completed

    1 trial

  46. Topiramate

    Janssen Cilag International NV

    Epilepsy

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Janssen Cilag International have?

46 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.